The corresponding
Bcl11a mouse gene is a common site of
retroviral integration in
myeloid leukemia, and may function as a leukemia disease gene, in part, through its interaction with BCL6. During hematopoietic cell differentiation, this gene is down-regulated. It is possibly involved in lymphoma pathogenesis since translocations associated with B-cell malignancies also deregulates its expression. In addition, BCL11A has been found to play a role in the suppression of fetal hemoglobin production. Therapeutic strategies aimed at increasing
fetal hemoglobin production in diseases such as
beta thalassemia and
sickle cell anemia by inhibiting BCL11A are currently being explored. Furthermore, heterozygous
de novo mutations in
BCL11A have been identified in an
intellectual disability disorder, accompanied with global developmental delay and
autism spectrum disorder. These mutations disrupt BCL11A homodimerization and transcriptional regulation. BCL11A has also been identified as an important gene of interest in type-2 diabetes. Methylation of BCl11A has been hypothesized to contribute to type-2 diabetes risk, while BCL11a loss in a human islet model was demonstrated to result in an increase in insulin secretion. == Interactions ==